PUR1800 Phase 1b study dosing is underway with data anticipated in Q4 2021
Pulmatrix completed FDA Type-C meeting and anticipates a Pulmazole Ph2b study start in Q1 2022
PUR3100 lead DHE (dihydroergotamine) formulation identified for pulmonary delivered acute migraine treatment
Cash runway extends beyond anticipated PUR1800 Ph1b, PUR3100 Ph1/Ph2 and Pulmazole Ph2b data milestones
PR Newswire
LEXINGTON, Mass., March 4, 2021